JNK

<p>Guggulsterone (Guggulsterone E&amp;Z) E&amp;Z is a 3-hydroxy steroid. It has a role as an androgen.</p>

<p>JNK-IN-7 (JNK inhibitor) is a selective JNK1/2/3 inhibitor (IC50: 1.54/1.99/0.75 nM).</p>

<p>CC-401 Hydrochloride (CC401 HCl) is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with antineoplastic activity.</p>

<p>Bentamapimod (AS 602801) is a novel, orally active inhibitor of JNK.</p>

<p>Astragaloside IV suppresses ERK1/2, JNK, MMP-2/9 in breast cancer; inhibits adenovirus and protects cardiovascular, immune, digestive, nervous systems.</p>

<p>JNK-IN-8 (JNK Inhibitor XVI) is an irreversible JNK1/2/4 inhibitor (IC50: 4.7/18.7/1 nM).</p>

<p>Epieriocalyxin A can suppress Caco-2 colon cancer cell growth. It could be a potential drug for colon cancer therapy in the future.</p>

<p>1.</p>

<p>IQ3 inhibits JNK3 (Kd 66 nM), JNK1/2, NF-κB/AP1 in THP1-Blue cells (IC50 1.4 μM), and reduces TNF-α/IL-6 production.</p>

<p>Indirubin-3′-oxime is an effective inhibitor of cyclin-dependent protein kinases, and may play an obligate role in neuronal apoptosis in Alzheimer's disease.</p>

<p>IQ-1S free acid (IQ-1S) is an effective and specific c-Jun N-Terminal Kinase Inhibitor. IQ-1S inhibits murine delayed-type hypersensitivity.</p>

<p>Sodium taurochenodeoxycholate: induces apoptosis, anti-inflammatory, boosts insulin, stimulates α2-cells, increases [Ca(2+)](c).</p>

<p>Fasudil hydrochloride (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK with Ki of 0.33 μM, 1.0 μM, 9.3 μM and 55 μM, respectively.</p>

<p>CC-90001 is an orally administered c-Jun N-terminal kinase (JNK) inhibitor with bias for JNK1 over JNK2.</p>

<p>Phytolaccaceae has anti-tumor activity, the mechanism may be related to the capacity of Esculentoside H for TNF release.</p>

<p>TCS JNK 5a (SC202671) is an effective, specific inhibitor of JNK3(pIC50= 6.7), JNK2(pIC50=6.5).</p>

<p>Ginsenoside Re (Ginsenoside B2) may have properties that inhibit or prevent the growth of tumors.</p>

<p>Juglanin is a JNK activator. Juglanin with inflammation and anti-tumor activities. It can induce apoptosis and autophagy on human breast cancer cells.</p>

<p>Tomatidine serves as an anti-inflammatory agent by inhibiting NF-κB and JNK signaling pathways.</p>

<p>Sesamolin and sesamin guard nerves, reduce microglia damage by blocking p38 MAPK and caspase-3, and curb nitric oxide in stimulated cells.</p>

<p>Pamapimod (R1503) (R-1503, Ro4402257) is a novel, selective inhibitor of p38 mitogen-activated protein kinase.</p>

<p>GSK649A is a novel activator of Satellite Cell Proliferation, it could enhance repair of Damaged Muscle.</p>

<p>SX 011 is a p38α inhibitor.</p>

<p>JNK-1-IN-1 is an inhibitor specifically targeting JNK-1, also exhibiting inhibition of MKK7 with an IC50 value of 7.8μM.</p>

<p>JNK3 inhibitor, potent and selective</p>

<p>TOPK-p38/JNK-IN-1 (Compound B12) is an orally active inhibitor of the TOPK-p38/JNK signaling pathway, with an IC50 value of 2.14 μM for the inhibition of NO</p>

<p>SR-3306 is a brain-penetrant and selective pan-JNK (JNK1/2/3) inhibitor with IC50 values ​​of 67 nM, 283 nM, 159 nM.Cost-effective and quality-assured.</p>

<p>BSJ-04-122: MKK4/7 inhibitor with IC50s of 4 nM &amp; 181 nM, used in cancer research.</p>

<p>SR-3737 is potent both JNK3 and p38 inhibitor.</p>

<p>J30-8 is a JNK3 inhibitor (IC50: 40 nM) with neuroprotective activity and can be used to study neurodegenerative diseases such as Alzheimer's disease.</p>

<p>JNK3 inhibitor-4: potent, selective JNK3 blocker (IC50=1.0nM), neuroprotective, BBB-permeable.</p>

<p>JNK-IN-11 inhibits JNK1/2/3 (IC50: 2.2/21.4/1.8 μM); promising for Alzheimer's/Parkinson's research.</p>

<p>JNK3 inhibitor-1: potent, selective, IC50 of 0.005 μM, orally bioavailable, brain-penetrant.</p>

<p>Ezatiostat HCl (TLK199) inhibits glutathione S-transferase, GSTP1-1 specifically, and may treat cytopenias.</p>

<p>TC ASK 10 is a potent, selective and orally active inhibitor of apoptosis signal-regulating kinase 1 (ASK1,IC50 = 14 nM). The IC50 value for ASK2 is 0.51 μM.</p>

<p>JNK3 Inhibitor-3 selectively blocks JNK3 (&gt;4.1 nM), crosses the blood-brain barrier, is orally active, and improves memory in dementia mice.</p>

<p>(±)-Perillaldehyde exhibits antidepressant effects in mice with stress-induced depressive-like behavior by modulating the olfactory nervous system. Additionally, it demonstrates anti-inflammatory activity by activating JNK in RAW264.7 cells and suppressing the expression of TNF-α, with an IC50 value of 171.7 μM.</p>

<p>JD118 is an inhibitor of JNK. It effectively suppresses the activity of JNK1 and the expression of cJun (1 - 135).</p>

<p>JNK-1-IN-5 (Compound 14) is a potent JNK1 inhibitor with sub-nanomolar efficacy. It effectively inhibits TGF-β-induced epithelial-mesenchymal transition and shows promise for research targeting JNK1 as an anti-pulmonary fibrosis agent.</p>

<p>p38 Kinase inhibitor 8 (Compound CCLXXVIII) is an orally active inhibitor targeting p38β and JNK2α2, with IC50 values of 6.3 nM and 53.6 nM, respectively. It has demonstrated anti-inflammatory effects in a rat model of collagen-induced arthritis.</p>

PT109 is a multikinase inhibitor that targets JNK and other kinases, playing a crucial role in anti-inflammatory, antioxidative, neurogenic, and synaptogenic processes. Specifically, PT109 inhibits JNK isoforms with the following IC50 values: JNK1 at 0.143 μM, JNK2 at 0.831 μM, and JNK3 at 0.285 μM. It also inhibits SGK isoforms (SGK1: IC50=1.34 μM; SGK2: IC50=5.6 μM; SGK3: IC50=26.4 μM) and ROCK2 (IC50=34 μM). Additionally, PT109 reprograms polymorphic glioblastoma multiforme (GBM) into oligodendroglia via the PTBP1/PKM1/2 pathway and alters the metabolic pattern of GBM to exhibit antiglioma activity.

<p>JD123 inhibits the activity of JNK1 and the expression of cJun (1-135). It is an ATP-competitive inhibitor specific to p38-γ MAPK and has no effect on ERK1, ERK2, p38-α, p38-β, and p38-δ.</p>

<p>TLR4/JNK/NF-κB-IN-1 (Racemic-11k) is an inhibitor of TLR4, JNK, and NF-κB. It suppresses NO production in LPS-stimulated RAW264.7 cells with an IC50 of 23.2 µM. By inhibiting TLR4 expression and reducing JNK phosphorylation, TLR4/JNK/NF-κB-IN-1 prevents NF-κB activation. This leads to a decrease in the transcription of inflammation-related genes, reducing the expression of iNOS and COX-2, and the production of inflammatory mediators such as NO, PGE2, and TNF-α, thereby exhibiting anti-inflammatory activity. TLR4/JNK/NF-κB-IN-1 holds potential in the study of inflammatory diseases, including rheumatoid arthritis and various other inflammatory conditions.</p>

<p>JNK-IN-19 (Compound Q8) is an inhibitor of c-Jun N-terminal kinase, utilized for the treatment and/or prevention of injuries prior to, during, or following surgery.</p>

<p>JNK-IN-21 (Compound 62) is an inhibitor of JNK-1.</p>

<p>JAK3-IN-13: Oral JAK3 inhibitor, selective &amp; potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.</p>

<p>JNK-1-IN-4 (Compound E1) is an inhibitor of JNK, targeting JNK-1, JNK-2, and JNK-3 with IC50 values of 2.7, 19.0, and 9.0 nM, respectively. This compound inhibits the phosphorylation of c-Jun and reduces the expression of TGF-β1-induced EMT markers (such as fibronectin and α-SMA). JNK-1-IN-4 exhibits favorable pharmacokinetic properties with a bioavailability of 69%. Additionally, it demonstrates antifibrotic effects in a Bleomycin-induced mouse model of idiopathic pulmonary fibrosis.</p>